NASDAQ:FOLD
Amicus Therapeutics Stock News
$9.48
-0.660 (-6.51%)
At Close: May 09, 2024
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2021
07:00am, Friday, 03'rd Sep 2021
PHILADELPHIA, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the
Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q2 2021 Results - Earnings Call Transcript
12:34am, Friday, 06'th Aug 2021
Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q2 2021 Results - Earnings Call Transcript
Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates
09:54am, Thursday, 05'th Aug 2021
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 9.52% and 8.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference
07:00am, Wednesday, 04'th Aug 2021
PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Vir
Amicus's Fabry Disease Medicine Gets European Approval For Use In Adolescents
08:50am, Monday, 02'nd Aug 2021
The European Commission has approved Amicus Therapeutics Inc (NASDAQ: FOLD) Galafold (migalastat) for use in adolescents with Fabry disease who have an amenable mutation. Galafold is already appr
Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease
07:00am, Monday, 02'nd Aug 2021
Galafold® is the First and Only Oral Therapy Approved in the EU for the Long-term Treatment of Adolescents with Fabry Disease Aged 12 years and older with an Amenable Mutation Galafold® is the First
Amicus Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021
07:00am, Tuesday, 27'th Jul 2021
PHILADELPHIA, July 27, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 5, 2021 at 8:
Amicus Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
07:00am, Friday, 28'th May 2021
PHILADELPHIA, May 28, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Goldman S
Amicus, Bloomin' Brands, Seagate and More Friday Afternoon Analyst Calls
12:26pm, Friday, 21'st May 2021
With the trading day more than halfway over, the markets were somewhat mixed going into the weekend.
Amicus Therapeutics Announces Upcoming Presentations at the 16th International Congress on Neuromuscular Diseases
07:00am, Friday, 21'st May 2021
PHILADELPHIA, May 21, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two posters for presentation highlighting its development program for Pompe disease at the 16th Inter
Amicus' (FOLD) Q1 Loss Wider Than Expected, Sales Up Y/Y
12:47pm, Tuesday, 11'th May 2021
Amicus (FOLD) reports a wider Q1 loss and sales miss estimates.
Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q1 2021 Results - Earnings Call Transcript
11:02am, Monday, 10'th May 2021
Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q1 2021 Results - Earnings Call Transcript
Recap: Amicus Therapeutics Q1 Earnings
08:01am, Monday, 10'th May 2021
Shares of Amicus Therapeutics (NASDAQ:FOLD) rose 0.6% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 28.57% over the past year to ($0.25), wh
Amicus Therapeutics to Present at Upcoming Investor Conferences in May 2021
07:00am, Friday, 07'th May 2021
PHILADELPHIA, May 07, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the fo
Amicus Therapeutics Concludes Pre-BLA Meeting With FDA For AT-GAA In Pompe Disease
08:30am, Monday, 03'rd May 2021
Amicus Therapeutics Inc (NASDAQ: FOLD) has completed a Type B Pre-Biologics License Application (BLA) meeting with the FDA for AT-GAA (cipaglucosidase alfa co-administered with miglustat) for Pomp